Phenex uses its Nuclear Receptor assay battery and its SNuRM® platform to analyze compounds from Sanofi Aventis on a service basis

Ludwigshafen, Germany, May 9th, 2007

Phenex Pharmaceuticals AG announced today that it provides services in compound and cofactor profiling at Nuclear Receptor drug targets for Sanofi Aventis. Nuclear Receptors, such as the steroid receptors, are important drug targets which are very relevant for the development of diabetic drugs, women’s or men’s health medicines, and certain cancer or cardiovascular drugs. Phenex has built a special technology platform around Nuclear Receptors, called SNuRM®, that allows to analyze differences between novel drug candidates regarding their potential to elicit wanted or unwanted effects. Phenex and Sanofi Aventis have now entered into a fee-for-service agreement to evaluate and use this SNuRM® technology from Phenex in their drug discovery research. In addition, Phenex will apply its panel of Nuclear Receptor assays, the broadest collection worldwide, to analyze Sanofi Aventis compounds with regard to Nuclear Receptor selectivity.

With Sanofi Aventis we have now won another top 10 pharma company as a customer,“ says Dr. Claus Kremoser, CEO of Phenex. He continues: “We are proud that our Nuclear Receptor technology platform is so highly recognized by Sanofi Aventis. They will employ our SNuRM® cofactor profiling technology as well as our NR assay battery in this agreement and this demonstrates that we have a superior technology basis for nuclear receptor drug discovery. We thank Sanofi Aventis for their trust in us. ”

Contact

Waldhofer Str. 104
69123 Heidelberg
Germany
Phone: +49 6221 65282-0
Fax: +49 6221 65282-10
Dr. Claus Kremoser
Thomas Hoffmann
mailto: info@phenex-pharma.com

About Phenex Pharmaceuticals AG

Phenex is a privately held drug discovery and development company headquartered in Heidelberg. The biopharmaceutical company can now build on nineteen years of expertise in exploring and defining innovative, potent and selective new drug candidates from small molecules. Phenex´s R&D activities are centered around diseases of liver such as NASH and cancer.